Millendo Therapeutics (NASDAQ:MLND) Cut to Hold at ValuEngine

Millendo Therapeutics (NASDAQ:MLND) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, ValuEngine reports.

Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Millendo Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Jefferies Financial Group began coverage on Millendo Therapeutics in a research report on Wednesday, March 13th. They issued a “buy” rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Millendo Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $23.25.

Shares of MLND stock opened at $12.95 on Wednesday. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. Millendo Therapeutics has a twelve month low of $6.77 and a twelve month high of $17.34. The firm has a market cap of $175.35 million, a P/E ratio of -0.74 and a beta of 3.05.

Millendo Therapeutics (NASDAQ:MLND) last posted its earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.08). Millendo Therapeutics had a negative net margin of 10,128.37% and a negative return on equity of 52.20%. On average, research analysts expect that Millendo Therapeutics will post -3.25 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Frazier Management LLC bought a new position in Millendo Therapeutics in the fourth quarter valued at about $11,103,000. Great Point Partners LLC bought a new position in Millendo Therapeutics in the fourth quarter valued at about $10,240,000. Adams Street Partners LLC acquired a new stake in shares of Millendo Therapeutics in the fourth quarter valued at about $3,285,000. Prosight Management LP increased its stake in shares of Millendo Therapeutics by 5.5% in the first quarter. Prosight Management LP now owns 270,762 shares of the company’s stock valued at $4,061,000 after buying an additional 14,023 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Millendo Therapeutics by 16.5% in the first quarter. Renaissance Technologies LLC now owns 104,297 shares of the company’s stock valued at $1,564,000 after buying an additional 14,790 shares during the period. Hedge funds and other institutional investors own 44.07% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Story: What is cost of equity?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.